Literature DB >> 10638574

The SIBDQ: further validation in ulcerative colitis patients.

S W Han1, W Gregory, D Nylander, A Tanner, P Trewby, R Barton, M Welfare.   

Abstract

OBJECTIVE: The Inflammatory Bowel Disease Questionnaire (IBDQ) is an instrument that assesses quality of life in patients with inflammatory bowel disease. It has 32 items in four domains. The short form of the IBDQ (SIBDQ) was developed in Canadian Crohn's disease patients for use in clinical practice. Patients with ulcerative colitis might require a different form of the SIBDQ. Our aim was to design and validate a SIBDQ for patients with ulcerative colitis and to compare this to the Crohn's SIBDQ.
METHODS: We recruited 122 patients with colitis as an initial sample. Using linear regression modeling, the 10 items that best predicted the total IBDQ score were identified. The colitis and Crohn's versions of the SIBDQ were compared by univariate linear regression with the total IBDQ score in two other cohorts of colitis patients.
RESULTS: Ten items explained 97% of the variance of the total IBDQ score in our first cohort. These were items 1 and 9 (bowel); 7, 11, 21, 30 (emotional); 2 and 10 (systemic); and 12 and 28 (social). Only three items were shared with the Crohn's SIBDQ. The R2 for both SIBDQs with the total IBDQ score in the other cohorts were very high (> or =0.95), although the Colitis SIBDQ showed better internal consistency.
CONCLUSIONS: The development of a SIBDQ for patients with ulcerative colitis did not reveal any clear advantage over the original version of the SIBDQ. Further studies are required to determine the role of the SIBDQ in routine clinical practice.

Entities:  

Mesh:

Year:  2000        PMID: 10638574     DOI: 10.1111/j.1572-0241.2000.01676.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  9 in total

1.  Health-related quality of life in inflammatory bowel disease in a Danish population-based inception cohort.

Authors:  Lea K Christiansen; Bobby Lo; Flemming Bendtsen; Ida Vind; Marianne K Vester-Andersen; Johan Burisch
Journal:  United European Gastroenterol J       Date:  2019-05-17       Impact factor: 4.623

2.  A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis.

Authors:  Silvio Danese; Ailsa Hart; Axel Dignass; Gionata Fiorino; Edouard Louis; Stefanos Bonovas; Geert D'Haens; Iris Dotan; Gerhard Rogler; Kristine Paridaens; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2019-07-17       Impact factor: 4.623

3.  Impact of pain on health-related quality of life in patients with inflammatory bowel disease.

Authors:  Anja Schirbel; Anne Reichert; Stephanie Roll; Daniel C Baumgart; Carsten Büning; Bianca Wittig; Bertram Wiedenmann; Axel Dignass; Andreas Sturm
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

4.  Abdominal pain in ulcerative colitis.

Authors:  Matthew D Coates; Mayank Lahoti; David G Binion; Eva M Szigethy; Miguel D Regueiro; Klaus Bielefeldt
Journal:  Inflamm Bowel Dis       Date:  2013-09       Impact factor: 5.325

5.  Chronotype, social jet lag, sleep debt and food timing in inflammatory bowel disease.

Authors:  Prachi S Chakradeo; Ali Keshavarzian; Shubha Singh; Akram E Dera; James Philip G Esteban; Alice A Lee; Helen J Burgess; Louis Fogg; Garth R Swanson
Journal:  Sleep Med       Date:  2018-08-17       Impact factor: 3.492

6.  Quality of life after proctocolectomy and ileal pouch-anal anastomosis in patients with ulcerative colitis.

Authors:  Steffen Koerdt; Ekkehard C Jehle; Martin E Kreis; Michael S Kasparek
Journal:  Int J Colorectal Dis       Date:  2013-12-27       Impact factor: 2.571

7.  The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX ® formulated delayed-release mesalamine.

Authors:  Aaron Yarlas; Linnette Yen; Paul Hodgkins
Journal:  Qual Life Res       Date:  2014-09-06       Impact factor: 4.147

8.  Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study.

Authors:  Mary Kaye Willian; Geert D'Haens; Aaron Yarlas; Ashish V Joshi
Journal:  J Patient Rep Outcomes       Date:  2018-04-27

9.  Systematic Review of Development and Content Validity of Patient-reported Outcome Measures in Inflammatory Bowel Disease: Do We Measure What We Measure?

Authors:  Emma M van Andel; Brechtje D M Koopmann; Femke Crouwel; Casper G Noomen; Nanne K H de Boer; Dirk P van Asseldonk; Lidwine B Mokkink
Journal:  J Crohns Colitis       Date:  2020-09-16       Impact factor: 9.071

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.